Visualization of Somatostatin Receptors in Prostate Cancer and its Bone Metastases with Ga-68–DOTATOC PET/CT

Abstract

In prostate cancer and its bone metastases, DOTATOC-affine somatostatin receptors (subtype 2 and 5) can be visualized with Ga-68-DOTATOC PET/CT. But their expression is so weak that other conjugates should be tested for receptor-mediated therapies which are better at addressing the prostate cancer-specific somatostatin receptor subtypes 1 and 4-or even other receptors.

(Carboxymethyl–Dextran)‐Modified Magnetic Nanoparticles Conjugated to Octreotide for MRI Applications

“…The peptide octreotide (OC), a somatostatin analogue that specifically targets somatostatin receptors, was used as a model drug and drug-delivery vehicle to transport MNPs into biological tissue. [19,37] In this project, we choose pancreatic cancer cells Bx-PC3 and colon cancer cells HCT-116 since they differ with respect to a somatostatin receptor and thus their ability to internalize material by endocytosis. Our result of a study employing the reverse transcription polymerase chain reaction (RT-PCR) is shown in Figure 4.…”

PET and PET/CT with68Gallium-Labeled Somatostatin Analogues in Non GEP-NETs Tumors

“…Luboldt et al [84] assessed SSTR expression in 20 patients with advanced prostate cancer to potentially guide SSTR-mediated therapies. On a side-by-side analysis only 30% of bone scintigraphy-positive metastases were seen with 68 Ga-DOTATOC PET/CT.…”

Positron Emission Tomography and Computer Tomography (PET/CT) in Prostate, Bladder, and Testicular Cancers

“…tastases [52], but not always [53]. Other radiotracers such as somatostatin analogs could be visualized in prostate cancer and bone metastases with a low expression, however, so that more research on other somatostatin receptors subtypes or other receptor is required [54]. Large-scale studies are still needed to determine the exact value and cost-efficiency of this method.…”